Sleep apnea product company Zyppah reported on Monday the receipt of the 510k clearance from the US FDA for the launch of the first OTC (over-the-counter) dual action anti-snoring device Zyppah.
As of 21 January 2019, the company and its creator, Dr Jonathan Greenburg, DDS, received the US FDA registration #K182312 for Zyppah, which has been on the market for six years.
The company said the US FDA's certification included a "first" ranking when compared against the category monograph to feature a wholly unique, dual-action feature that advances the mandible while repositioning the tongue to keep it from blocking the airway; the reason snoring occurs.
In connection with the launch, Zyppah retails for USD99.95 and is available on Zyppah.com and Amazon.com.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT